BACKGROUND: Mutations in the RAS gene in the thyroid gland result in the activation of signaling pathways and are associated with a follicular growth pattern and the probability of a carcinoma outcome ranging from 74% to 87%. In the current study, the authors investigated the cytopathologic and histopathologic features of common RAS mutation subtypes. METHODS: Malignant, indeterminate, and selected benign thyroid cytology cases were tested prospectively for the presence of NRAS61, HRAS61, and KRAS12/13 mutations. For each case, the Bethesda System for thyroid cytopathology diagnosis, additional cytologic descriptors, and surgical pathology outcomes were documented. The Fisher exact test and Wilcoxon 2-sample test were used for statistical comparison between the groups. RESULTS: A total of 204 thyroid fine-needle aspiration cases with RAS mutations (93.6% of which were associated with indeterminate cytopathology diagnoses) and corresponding surgical pathology resection specimens were identified. The KRAS12/13 mutation was associated with a significantly lower carcinoma outcome (41.7%) when compared with HRAS61 (95.5%) and NRAS61 (86.8%) mutations (P<.0001). Furthermore, oncocytic change was observed in a significantly higher percentage of cytology and resection specimens with KRAS12/13 mutations (66.7% and 75.0%, respectively) in comparison with those with HRAS61 (4.5% and 4.5%, respectively) and NRAS61 (15.4% and 14.7%, respectively) mutations (P<.0001). RAS mutations also were identified in cases of poorly differentiated carcinoma (NRAS61), anaplastic carcinoma (HRAS61), and medullary thyroid carcinoma (HRAS61 and KRAS12/13). CONCLUSIONS: Subclassification of RAS mutations in conjunction with cytopathologic evaluation improves presurgical risk stratification, provides better insight into lesional characteristics, and may influence patient management. In particular, KRAS12/13-mutated thyroid nodules were found to be different from HRAS61-mutated and NRAS61-mutated nodules with regard to cytopathologic and surgical outcome characteristics.
BACKGROUND: Mutations in the RAS gene in the thyroid gland result in the activation of signaling pathways and are associated with a follicular growth pattern and the probability of a carcinoma outcome ranging from 74% to 87%. In the current study, the authors investigated the cytopathologic and histopathologic features of common RAS mutation subtypes. METHODS: Malignant, indeterminate, and selected benign thyroid cytology cases were tested prospectively for the presence of NRAS61, HRAS61, and KRAS12/13 mutations. For each case, the Bethesda System for thyroid cytopathology diagnosis, additional cytologic descriptors, and surgical pathology outcomes were documented. The Fisher exact test and Wilcoxon 2-sample test were used for statistical comparison between the groups. RESULTS: A total of 204 thyroid fine-needle aspiration cases with RAS mutations (93.6% of which were associated with indeterminate cytopathology diagnoses) and corresponding surgical pathology resection specimens were identified. The KRAS12/13 mutation was associated with a significantly lower carcinoma outcome (41.7%) when compared with HRAS61 (95.5%) and NRAS61 (86.8%) mutations (P<.0001). Furthermore, oncocytic change was observed in a significantly higher percentage of cytology and resection specimens with KRAS12/13 mutations (66.7% and 75.0%, respectively) in comparison with those with HRAS61 (4.5% and 4.5%, respectively) and NRAS61 (15.4% and 14.7%, respectively) mutations (P<.0001). RAS mutations also were identified in cases of poorly differentiated carcinoma (NRAS61), anaplastic carcinoma (HRAS61), and medullary thyroid carcinoma (HRAS61 and KRAS12/13). CONCLUSIONS: Subclassification of RAS mutations in conjunction with cytopathologic evaluation improves presurgical risk stratification, provides better insight into lesional characteristics, and may influence patient management. In particular, KRAS12/13-mutated thyroid nodules were found to be different from HRAS61-mutated and NRAS61-mutated nodules with regard to cytopathologic and surgical outcome characteristics.
Authors: Pablo Valderrabano; Laila Khazai; Zachary J Thompson; Kristen J Otto; Julie E Hallanger-Johnson; Christine H Chung; Barbara A Centeno; Bryan McIver Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-09-01 Impact factor: 6.223
Authors: Pablo Valderrabano; Laila Khazai; Marino E Leon; Zachary J Thompson; Zhenjun Ma; Christine H Chung; Julie E Hallanger-Johnson; Kristen J Otto; Kara D Rogers; Barbara A Centeno; Bryan McIver Journal: Endocr Relat Cancer Date: 2017-01-19 Impact factor: 5.678
Authors: Snehal G Patel; Sally E Carty; Kelly L McCoy; N Paul Ohori; Shane O LeBeau; Raja R Seethala; Marina N Nikiforova; Yuri E Nikiforov; Linwah Yip Journal: Surgery Date: 2016-11-15 Impact factor: 3.982
Authors: Nicole A Cipriani; Daniel N Johnson; David H Sarne; Peter Angelos; Ward Reeves; Tatjana Antic Journal: Endocr Pathol Date: 2022-10-13 Impact factor: 4.056
Authors: Linwah Yip; Marina N Nikiforova; Jenny Y Yoo; Kelly L McCoy; Michael T Stang; Michaele J Armstrong; Kristina J Nicholson; N Paul Ohori; Christopher Coyne; Steven P Hodak; Robert L Ferris; Shane O LeBeau; Yuri E Nikiforov; Sally E Carty Journal: Ann Surg Date: 2015-09 Impact factor: 12.969
Authors: Juan C Hernandez-Prera; Pablo Valderrabano; Jordan H Creed; Janis V de la Iglesia; Robbert J C Slebos; Barbara A Centeno; Valentina Tarasova; Julie Hallanger-Johnson; Colleen Veloski; Kristen J Otto; Bruce M Wenig; Sean J Yoder; Cesar A Lam; Derek S Park; Alexander R Anderson; Natarajan Raghunand; Anders Berglund; Jimmy Caudell; Travis A Gerke; Christine H Chung Journal: Thyroid Date: 2020-08-25 Impact factor: 6.568
Authors: Marco Medici; Norra Kwong; Trevor E Angell; Ellen Marqusee; Matthew I Kim; Mary C Frates; Carol B Benson; Edmund S Cibas; Justine A Barletta; Jeffrey F Krane; Daniel T Ruan; Nancy L Cho; Atul A Gawande; Francis D Moore; Erik K Alexander Journal: BMC Med Date: 2015-08-07 Impact factor: 8.775